On January 7, 2021 Through this license agreement, SIRION Biotech GmbH ("SIRION") reported that granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer LentiBOOST (Press release, SIRION Biotech, JAN 7, 2021, View Source [SID1234573654]). This product complements Cellectis’ portfolio of technologies involved in manufacturing allogeneic CAR T-cells. SIRION is entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Allogeneic CAR-T cell therapy represent a future-defining shift in simplicity, availability, and cost efficiency of immune-oncology approaches. Engineering effective allogeneic T-cells, in contrast to patient derived cells, elevates the technology to the level of a realistic off-the-shelf product.

Dr. Christian Thirion, CEO and founder of SIRION explains: "LentiBOOST improves lentiviral transduction of difficult cell types like hematopoietic stem cells, and in addition generates stable integration of large constructs generally needed to generate CAR-T cells."

"We are delighted that our product will help further develop affordable allogeneic cancer treatments that will, once approved, benefit patients with unmet needs," says SVP BD & Licensing, Dr. Sabine Ott.